You are viewing an incomplete version of our website. Please click to reload the website as full version.

Aperçu des produits pour anti-PIK3CA (PIK3CA) Anticorps

Full name:
anti-Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide Anticorps (PIK3CA)
Chez sont 153 Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) Anticorps de 26 de différents fournisseurs disponibles. De plus, nous expédions PIK3CA Kits (6) et PIK3CA Protéines (3) et beaucoup plus de produits pour cette protéine. Un total de 170 PIK3CA produits sont actuellement listés.
6330412C24Rik, C-P3K, caPI3K, CLOVE, CWS5, MCAP, MCM, MCMTC, p110, p110-alpha, p110alpha, pi3-k, PI3-kinase, PI3K, PI3K-alpha
afficher tous les anticorps Gène GeneID UniProt
PIK3CA 18706 P42337
PIK3CA 5290 P42336
PIK3CA 170911  

Afficher toutes les espèces

Afficher tous les synonymes

Réactivités les plus populaires pour anti-PIK3CA (PIK3CA) Anticorps

Sélectionnez vos espèces et l'application

anti-Mouse (Murine) PIK3CA Anticorps:

anti-Human PIK3CA Anticorps:

anti-Rat (Rattus) PIK3CA Anticorps:

Tous anti-PIK3CA Anticorps disponible

Vous arrivez à notre recherche pré-filtrée.

anti-PIK3CA Anticorps mieux référencés

  1. Human Monoclonal PIK3CA Primary Antibody pour IF, WB - ABIN968518 : Funaki, Katagiri, Kanda, Anai, Nawano, Ogihara, Inukai, Fukushima, Ono, Yazaki, Kikuchi, Oka, Asano: p85/p110-type phosphatidylinositol kinase phosphorylates not only the D-3, but also the D-4 position of the inositol ring. dans The Journal of biological chemistry 1999 (PubMed)
    Show all 5 references for ABIN968518

  2. Chicken Monoclonal PIK3CA Primary Antibody pour BI, IP - ABIN967707 : Cantley, Auger, Carpenter, Duckworth, Graziani, Kapeller, Soltoff: Oncogenes and signal transduction. dans Cell 1991 (PubMed)
    Show all 5 references for ABIN967707

  3. Human Polyclonal PIK3CA Primary Antibody pour EIA, IHC (p) - ABIN4620510 : Broderick, Di, Parrett, Samuels, Cummins, McLendon, Fults, Velculescu, Bigner, Yan: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. dans Cancer research 2004 (PubMed)
    Show all 4 references for ABIN4620510

  4. Human Monoclonal PIK3CA Primary Antibody pour ICC, FACS - ABIN969555 : Edwards, Witherspoon, Wang, Afrasiabi, Pham, Birnbaumer, Lipkin: Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. dans Cancer research 2009 (PubMed)
    Show all 3 references for ABIN969555

  5. Human Polyclonal PIK3CA Primary Antibody pour FACS, IHC (p) - ABIN1882113 : Singh, Reddy, Goberdhan, Walsh, Dao, Ngai, Chou, O-Charoenrat, Levine, Rao, Stoffel: p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. dans Genes & development 2002 (PubMed)
    Show all 3 references for ABIN1882113

  6. Human Polyclonal PIK3CA Primary Antibody pour IHC (p), WB - ABIN392560 : Shayesteh, Lu, Kuo, Baldocchi, Godfrey, Collins, Pinkel, Powell, Mills, Gray: PIK3CA is implicated as an oncogene in ovarian cancer. dans Nature genetics 1999 (PubMed)
    Show all 3 references for ABIN392560

  7. Human Polyclonal PIK3CA Primary Antibody pour EIA, WB - ABIN360221 : Zhao, Vogt: Class I PI3K in oncogenic cellular transformation. dans Oncogene 2008 (PubMed)
    Show all 3 references for ABIN360221

  8. Human Monoclonal PIK3CA Primary Antibody pour EIA, FACS - ABIN1108651 : Hwang, Ryu, Chung, Kim, Park, Chae, Chae, Kwon: Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. dans Oncogene 2004 (PubMed)
    Show all 2 references for ABIN1108651

  9. Human Polyclonal PIK3CA Primary Antibody pour FACS, IF (p) - ABIN677198 : Paul-Samojedny, Suchanek, Borkowska, Pude?ko, Owczarek, Kowalczyk, Machnik, Fila-Dani?ow, Kowalski: Knockdown of AKT3 (PKB?) and PI3KCA suppresses cell viability and proliferation and induces the apoptosis of glioblastoma multiforme T98G cells. dans BioMed research international 2014 (PubMed)

  10. Cow (Bovine) Polyclonal PIK3CA Primary Antibody pour EIA, IHC (p) - ABIN375147 : Abubaker, Bavi, Al-Haqawi, Jehan, Munkarah, Uddin, Al-Kuraya: PIK3CA alterations in Middle Eastern ovarian cancers. dans Molecular cancer 2009 (PubMed)

Plus d’anticorps contre PIK3CA partenaires d’interaction

Mouse (Murine) Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. The mRNA levels of leptin (Montrer LEP Anticorps) and of 17-beta-dehydrogenase 3, and enzyme important for testosterone production, were significantly higher in the testis of adult alpha-/- males( PI3K catalytic subunit p110alpha deletion).

  2. Results suggest a role of ST6GalNAc I (Montrer ST6GALNAC1 Anticorps) in promoting the growth and invasion of hepatocarcinoma cells through regulating PI3K/AKT (Montrer AKT1 Anticorps)/NF-kappa B (Montrer NFKB1 Anticorps) signaling, and ST6GalNAc I (Montrer ST6GALNAC1 Anticorps) might be a marker for the prognosis and therapy of hepatocarcinoma.

  3. PI3K signaling plays a modulatory role in the regulation of the transcriptional rhythm of the Dbp (Montrer GC Anticorps) gene by targeting BMAL1 (Montrer ARNTL Anticorps) and CLOCK.

  4. Analysis of 18 signalling signatures revealed that PI3K signalling is significantly induced whereas EGFR (Montrer EGFR Anticorps) signalling is significantly reduced in Pten (Montrer PTEN Anticorps)() versus PIK3CA(H1047R) tumors. Thus, Pten (Montrer PTEN Anticorps)() and PIK3CA(H1047R) tumors exhibit discernable differences that may impact tumorigenesis and response to therapy.

  5. activating PIK3CA mutations gives rise to sporadic venous malformations in mice, which closely resemble the histology of the human disease.

  6. These data demonstrate a causal relationship between activating Pik3ca mutations and the genesis of vascular malformations.

  7. data demonstrate that the PI3K p110alpha-Akt (Montrer AKT1 Anticorps)/Rac1 and NOX1 (Montrer NOX1 Anticorps) signalling pathways play a pivotal role in VEGF (Montrer VEGFA Anticorps)-induced vascular differentiation and cell migration.

  8. miR (Montrer MLXIP Anticorps)-490-5p functions as a tumour suppressor in renal carcinoma (Montrer TSC2 Anticorps) by targeting PIK3CA

  9. Thus, non-canonical phosphoinositide 3-kinase-antagonism by Itpkb (Montrer ITPKB Anticorps) restricts pre-T cell receptor (Montrer PTCRA Anticorps) induced metabolic activation to enforce coincidence-detection of pre-T cell receptor (Montrer PTCRA Anticorps) expression and Notch (Montrer NOTCH1 Anticorps)-engagement.

  10. Data show that RNA silencing of CCN family member 1 (Montrer CYR61 Anticorps) protein (CCN1 (Montrer CCNA2 Anticorps)) inhibits retinal neovascularization (RNV) by inhibiting phosphoinositide 3-kinase (PI3K)/AKT (Montrer AKT1 Anticorps) protein signaling in mouse pup model of oxygen-induced retinopathy (OIR).

Human Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. Bis (Montrer BAG3 Anticorps)(acetylacetonato)-oxidovanadium(IV) and sodium metavanadate induced the activation of both PI3K/AKT (Montrer AKT1 Anticorps) and MAPK/ERK (Montrer MAPK1 Anticorps) signaling pathways dose- and time-dependently.

  2. PIK3CA and AKT1 (Montrer AKT1 Anticorps) are frequently mutated in Hidradenoma papilliferum (HP) tumours (29% and 14%, respectively). PIK3CA/AKT1 (Montrer AKT1 Anticorps) pathway alterations in HP further support the hypothesis that HP is the vulvar (anogenital mammary-like gland) analogue of breast intraductal papilloma.

  3. observations during clinical tumor genotyping suggest that when other pro-oncogenic pathways are mutated along with PIK3CA, then, PIK3CA inhibition alone may not be effective and combination therapy may be warranted

  4. Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irrespective of the degree of endocrine resistance, hormone-receptor (Montrer NR4A1 Anticorps) expression level, and PIK3CA mutational status. The combination could be considered as a therapeutic option for patients with HER2 (Montrer ERBB2 Anticorps)-negative breast cancer

  5. Findings show that calmodulin (CaM (Montrer CALM1 Anticorps)) stimulates phosphoinositide-3-kinase (PI3K) lipid kinase activity by binding MARCKS (Montrer MARCKS Anticorps) and displacing it from phosphatidylinositol 4,5-bisphosphate (PIP2) headgroups, thereby releasing free PIP2 that recruits active PI3K to the membrane and serves as the substrate for the generation of phosphatidylinositol 3,4,5-trisphosphate (PIP3).

  6. PIK3CA mutation is associated with salivary duct carcinoma.

  7. PIK3CA E545K/E542K mutations are associated with everolimus resistance in breast cancer.

  8. A recursively partitioned mixture model of all 3 somatic alteration burden measures resulted in classes of tumors whose epigenetic and genetic burden profile were associated with the PAM50 subtype and mutations in TP53 (Montrer TP53 Anticorps), PIK3CA, and CDH1 (Montrer CDH1 Anticorps)

  9. Combined inhibition of PI3K and PARP (Montrer COL11A2 Anticorps) effectively synergized to block the growth of three wild-type PIK3CA ovarian cancer cell lines and explants of a primary ovarian tumor specimen.

  10. PI3K protein was expressed in 81.3% (91/112) of all ESCC samples, whereas it was found in only 4.9% (5/56) of adjacent normal cells.PIK3CA gene mutations were highly correlated with age, tobacco use, and clinical stage (p<0.05), but not with gender, location, alcohol use, lymph node metastasis, or degree of differentiation. PI3K protein expression was not statistically correlated with PIK3CA gene mutations.

Cow (Bovine) Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. There are multiple conformations in equilibrium during the course of PI3K SH3 domain (Montrer ITSN1 Anticorps) unfolding.

  2. PI3K has a role in activation of 5'-AMP (Montrer TMPRSS5 Anticorps)-activated kinase during hypoxia-reoxygenation of bovine aortic endothelial cells

  3. Production of PtdIns3P by PI3K-C2alpha (Montrer PIK3C2A Anticorps) is required for acquisition of fusion competence in neurosecretion.

  4. crystallographic and biochemical approaches used to gain insight into activating mutations in two noncatalytic p110alpha domains-the adaptor-binding and the helical domains

PIK3CA profil antigène

Antigen Summary

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers.

Alternative names and synonyms associated with PIK3CA

  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) anticorps
  • Phosphoinositide-3-kinase, catalytic, alpha polypeptide (GL50803_14855) anticorps
  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca) anticorps
  • phosphoinositide-3-kinase, catalytic, alpha polypeptide (LOC100337822) anticorps
  • phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca) anticorps
  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (Pik3ca) anticorps
  • phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) anticorps
  • 6330412C24Rik anticorps
  • C-P3K anticorps
  • caPI3K anticorps
  • CLOVE anticorps
  • CWS5 anticorps
  • MCAP anticorps
  • MCM anticorps
  • MCMTC anticorps
  • p110 anticorps
  • p110-alpha anticorps
  • p110alpha anticorps
  • pi3-k anticorps
  • PI3-kinase anticorps
  • PI3K anticorps
  • PI3K-alpha anticorps

Protein level used designations for PIK3CA

phosphoinositide-3-kinase, catalytic, alpha polypeptide , Phosphoinositide-3-kinase, catalytic, alpha polypeptide , PI3-kinase subunit alpha , PI3K-alpha , PI3Kalpha , phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha , phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform , phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform , phosphoinositide-3-kinase catalytic alpha polypeptide , ptdIns-3-kinase subunit alpha , ptdIns-3-kinase subunit p110-alpha , serine/threonine protein kinase PIK3CA , PI3-kinase p110 subunit alpha , phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha , phosphatidylinositol 3-kinase, catalytic, alpha polypeptide , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform , PI3K , p110alpha , ptdIns-3-kinase p110 , phosphoinositide 3-kinase catalytic subunit

460858 Pan troglodytes
5702156 Giardia lamblia ATCC 50803
100144924 Xenopus (Silurana) tropicalis
100229768 Taeniopygia guttata
100337822 Oryctolagus cuniculus
18706 Mus musculus
5290 Homo sapiens
282306 Bos taurus
170911 Rattus norvegicus
488084 Canis lupus familiaris
424971 Gallus gallus
Fournisseurs de qualité sélectionnés pour anti-PIK3CA (PIK3CA) Anticorps
Avez-vous cherché autre chose?